RESUMEN
Infection with the intracellular protozoan parasite Toxoplasma gondii (T. gondii) causes health problems to both humans and livestock and has a large economic impact worldwide. The immune response in sheep following infection with T. gondii was evaluated using six different combinations of plasmid DNA, recombinant antigen and adjuvant. Sheep were generally vaccinated twice by intramuscular injection with plasmid DNA containing gene sequences for either the surface antigen (SAG1) or the rhoptry protein (ROP1) of T. gondii. Two of the groups injected with plasmid DNA SAG1 were boosted with recombinant protein (SAG1). We investigated the efficacy of including oligodeoxynucleotides (ODN) that contain CG motifs (CpG) and the gene coding for ovine granulocyte-macrophage colony stimulating factor (GM-CSF) as potential adjuvants. Administration of the plasmid encoding the ROP1 gene significantly enhanced both IFN-gamma production from peripheral blood cells when cultured in vitro with Toxoplasma antigen, and ROP1-specific IgG1 and IgG2 antibody levels present in serum. However, injection with SAG1 did not stimulate IFN-gamma production. These results indicate the potential of ROP1, given as plasmid DNA, as a potential vaccine candidate to protect sheep against T. gondii infection.
Asunto(s)
Antígenos de Protozoos/inmunología , Proteínas de la Membrana/inmunología , Proteínas Protozoarias/inmunología , Vacunas Antiprotozoos/inmunología , Toxoplasma/inmunología , Toxoplasmosis Animal/inmunología , Vacunación , Vacunas de ADN/inmunología , Adyuvantes Inmunológicos , Animales , Anticuerpos Antiprotozoarios/sangre , Anticuerpos Antiprotozoarios/inmunología , Especificidad de Anticuerpos , Antígenos de Protozoos/genética , Células Cultivadas , Femenino , Factor Estimulante de Colonias de Granulocitos y Macrófagos/inmunología , Esquemas de Inmunización , Inmunoglobulina G/sangre , Inyecciones Intramusculares , Interferón gamma/biosíntesis , Proteínas de la Membrana/genética , Oligodesoxirribonucleótidos/inmunología , Plásmidos/genética , Proteínas Protozoarias/genética , Vacunas Antiprotozoos/administración & dosificación , Vacunas Antiprotozoos/genética , Proteínas Recombinantes/biosíntesis , Proteínas Recombinantes/inmunología , Ovinos , Toxoplasmosis Animal/sangre , Vacunas de ADN/administración & dosificación , Vacunas de ADN/genéticaRESUMEN
OBJECTIVE: There is increasing evidence that gene copy-number variation influences phenotypic variation. Chemokine ligand 3-like 1 (CCL3L1) is encoded by a variable copy-number gene, and binds to several pro-inflammatory cytokine receptors, including chemokine receptor 5 (CCR5). Considering lymphocyte recruitment by beta-chemokines is a feature of autoimmunity, and that the CCR5Delta32 variant is associated with protection to rheumatoid arthritis (RA), we hypothesised that CCL3L1 copy-number influences susceptibility to RA and type 1 diabetes (T1D). METHODS: We measured CCL3L1 copy-number in 1136 RA cases from New Zealand (NZ) and the UK, 252 NZ T1D cases and a total of 1470 controls. All subjects were ancestrally Caucasian. RESULTS: A copy-number higher than 2 (the most common copy number) was a risk factor for RA in the NZ cohort (odds ratio (OR) 1.34, 95% CI 1.08-1.66, p = 0.009) but not the smaller UK RA cohort (OR 1.09, 95% CI 0.75-1.60, p = 0.643). There was evidence for association in the T1D cohort (OR 1.46, 95% CI 0.98-2.20, p = 0.064) and in the combined RA/T1D cohort (OR 1.30, 95% CI 1.00-1.54, p = 0.003). Genetic interaction between CCL3L1 dosage and CCR5 genotype was found; the increased genetic risk conferred by higher CCL3L1 copy-number was ablated by a dysfunctional CCR5 (CCR5Delta32). CONCLUSIONS: These data suggest that increased CCL3L1 expression may enhance inflammatory responses and increase the chance of autoimmune disease. Genetic interaction data were consistent with a biologically plausible model; CCR5Delta32 protects against RA and T1D by blocking signalling through the CCR5 pathway, mitigating the pro-inflammatory effects of excess CCL3L1.
Asunto(s)
Artritis Reumatoide/genética , Quimiocinas CC/genética , Dosificación de Gen , Estudios de Cohortes , Diabetes Mellitus Tipo 2/genética , Femenino , Predisposición Genética a la Enfermedad , Genotipo , Humanos , Masculino , Receptores CCR5/genética , Factores de RiesgoRESUMEN
Early stage rheumatoid arthritis (RA) is often difficult to diagnose because initial symptoms are non-specific. To aid diagnosis, suitable serological diagnostic markers are sought. Elevated levels of soluble MHC class II (soluble human leukocyte antigen; sHLA-DR) in human serum have been associated with rheumatoid and 'rheumatoid-like' autoimmune diseases. As a result, sHLA-DR has been suggested as a specific marker of RA. However, reported levels of sHLA-DR in sera of healthy donors vary significantly and the mechanism of release of HLA-DR into serum is poorly understood. Investigations into the diagnostic potential of this molecule necessitate the development of a sensitive and specific sHLA-DR assay. We have investigated multiple ELISA setups to develop such an assay and false positive signal has been carefully removed using a combination of isotype-matched controls and immuno-depletion. sHLA-DR levels in sera of RA patients were not significantly different from those in healthy donors which suggests sHLA-DR has limited utility in the diagnosis of RA. In RA patients, we detected high levels of sHLA-DR in aspirated synovial fluid (SF), but this did not correlate with sHLA-DR levels in serum.
Asunto(s)
Artritis Reumatoide/diagnóstico , Ensayo de Inmunoadsorción Enzimática/métodos , Antígenos HLA-DR/análisis , Líquido Sinovial/metabolismo , Artritis Reumatoide/sangre , Artritis Reumatoide/inmunología , Biomarcadores/análisis , Estudios de Casos y Controles , Línea Celular Tumoral , Femenino , Antígenos HLA-DR/sangre , Humanos , Masculino , Persona de Mediana Edad , Sensibilidad y Especificidad , Solubilidad , Líquido Sinovial/inmunologíaRESUMEN
DNA delivery of tumor antigens can activate specific immune attack on cancer cells. However, antigens may be weak, and immune capacity can be compromised. Fusion of genes encoding activating sequences to the tumor antigen sequence facilitates promotion and manipulation of effector pathways. Idiotypic determinants of B-cell tumors, encoded by the variable region genes, are clone-specific tumor antigens. When assembled as single-chain Fv (scFv) alone in a DNA vaccine, immunogenicity is low. Previously, we found that fusion of a sequence from tetanus toxin (fragment C; FrC) promoted anti-idiotypic protection against lymphoma and myeloma. We have now investigated an alternative fusion gene derived from a plant virus, potato virus X coat protein, a primary antigen in humans. When fused to scFv, the self-aggregating protein generates protection against lymphoma and myeloma. In contrast to scFv-FrC, protection against lymphoma is mediated by CD4+ T cells, as is protection against myeloma. Plant viral proteins offer new opportunities to activate immunity against linked T-cell epitopes to attack cancer.
Asunto(s)
Linfocitos B/metabolismo , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD4-Positivos/metabolismo , Leucemia/prevención & control , Plantas/genética , Plantas/virología , Vacunas de ADN/farmacología , Animales , Ensayo de Inmunoadsorción Enzimática , Humanos , Fragmentos de Inmunoglobulinas/química , Inmunoglobulina G/metabolismo , Linfoma/química , Ratones , Ratones Endogámicos C57BL , Mieloma Múltiple/prevención & control , Plásmidos/metabolismo , Ratas , Proteínas Recombinantes de Fusión/química , Proteínas Recombinantes de Fusión/metabolismo , Toxina Tetánica/química , Factores de TiempoAsunto(s)
Antígenos de Neoplasias/genética , Vacunas contra el Cáncer/uso terapéutico , Vacunas de ADN/uso terapéutico , Animales , Linfocitos B/inmunología , Vacunas contra el Cáncer/genética , Ensayos Clínicos como Asunto , Humanos , Idiotipos de Inmunoglobulinas , Linfoma de Células B/inmunología , Linfoma de Células B/terapia , Mieloma Múltiple/inmunología , Mieloma Múltiple/terapia , Neoplasias/inmunología , Neoplasias/terapia , Vacunas de ADN/genéticaRESUMEN
Pneumococcal serotype-specific anti-capsular polysaccharide antibodies protect against invasive pneumococcal disease. Within an individual the diversity of these antibodies is limited. To evaluate the repertoire of antibodies to pneumococcus and determine whether oligoclonality is seen both between serotypes and between individuals, we sampled the B cell repertoire induced by polysaccharide and conjugate vaccine in adult volunteers. Fifteen hybridomas secreting pneumococcus-specific monoclonal antibodies were generated from five volunteers. Ten were isotype switched, six were IgG2 and four were IgA. These included two isotype switch variants of the same clone. V(H)3 and V(kappa)2 were used by 10/15 and 7/13 of the sequenced clones, respectively, with identical genes, V(H)3-48 and V(kappa)2-A17 used by a number of volunteers to a variety of serotypes. VDJ junctional characteristics and complementarity-determining region (CDR) 3 length were variable. High levels of somatic mutation in CDR1 and 2, inconsistent with a primary response, were found in 10/11 of the isotype-switched antibodies, including those induced by plain polysaccharide antigens. These data suggest that wild-type infection or nasopharyngeal carriage of Streptococcus pneumoniae in adults may induce memory and the response to subsequent immunization with plain polysaccharide or conjugate pneumococcal vaccines may have the characteristics of a secondary response.
Asunto(s)
Diversidad de Anticuerpos/genética , Diversidad de Anticuerpos/inmunología , Genes de Inmunoglobulinas/genética , Vacunas Meningococicas , Polisacáridos Bacterianos/inmunología , Streptococcus pneumoniae/inmunología , Adulto , Secuencia de Aminoácidos , Anticuerpos Antibacterianos/genética , Anticuerpos Antibacterianos/inmunología , Anticuerpos Monoclonales/genética , Anticuerpos Monoclonales/inmunología , Afinidad de Anticuerpos , Especificidad de Anticuerpos , Linfocitos B/inmunología , Linfocitos B/metabolismo , Vacunas Bacterianas/inmunología , Reordenamiento Génico de Linfocito B/genética , Reordenamiento Génico de Linfocito B/inmunología , Vacuna Neumocócica Conjugada Heptavalente , Humanos , Hibridomas/inmunología , Hibridomas/metabolismo , Isotipos de Inmunoglobulinas/genética , Isotipos de Inmunoglobulinas/inmunología , Región Variable de Inmunoglobulina/genética , Región Variable de Inmunoglobulina/inmunología , Memoria Inmunológica/inmunología , Datos de Secuencia Molecular , Mutación/genética , Vacunas Neumococicas , Alineación de Secuencia , Serotipificación , Streptococcus pneumoniae/clasificación , Vacunas Conjugadas/inmunologíaRESUMEN
The antigenic specificities of 24 V4-34-encoded monoclonal antibodies were compared with the amino acid sequence. The specificities were divided into three categories, red blood cells, B lymphocytes and auto/exoantigens. Six anti-I monoclonal antibodies, with multiple substitutions in their VH region, did not bind B lymphocytes or auto/exoantigens. Reactivity to these two antigens segregated with the 16 anti-i monoclonal antibodies, which were derived from the near germline V4-34 gene. All anti-i monoclonal antibodies bound B lymphocytes, albeit with varying intensities. B-cell binding correlated with basic amino acids in the VH-CDR3. Reactivity to auto/exoantigens was demonstrated only by a subset anti-i monoclonal antibodies and did not correlate with B-lymphocyte or i-antigen binding. These anti-ssDNA reactive monoclonal antibodies had basic amino acids in the VH-CDR3, strongly supporting the suggested role of arginine in DNA binding. However, an arginine-rich CDR3 was not enough to ensure DNA reactivity, since six other anti-i monoclonal antibodies that fulfilled this criteria did not bind ssDNA. Thus it is possible that the anti-DNA reactivity of V4-34-encoded monoclonal antibodies is mediated by the classic antigen-binding groove generated by the CDRs of the heavy/light chains. In contrast, anti-B-cell/i-antigen reactivity is mediated, unconventionally, by the V4-34 protein with a dominant influence of the VH-CDR3.
Asunto(s)
Autoanticuerpos/inmunología , Autoantígenos/inmunología , Glicoesfingolípidos/inmunología , Secuencia de Aminoácidos , Anticuerpos Monoclonales/inmunología , Especificidad de Anticuerpos , Autoanticuerpos/genética , Línea Celular , Reacciones Cruzadas , Humanos , Cadenas Pesadas de Inmunoglobulina/genética , Cadenas Pesadas de Inmunoglobulina/inmunología , Región Variable de Inmunoglobulina/genética , Región Variable de Inmunoglobulina/inmunología , Datos de Secuencia MolecularRESUMEN
The ability of naked DNA to induce immune responses against encoded antigen has been clearly demonstrated for infectious diseases (1). In many cases, the induced immunity is able to protect against infection, and can approach the efficacy of exogenous antigen (2).
RESUMEN
To gain insight into the routes of presentation of pathogen sequences via DNA vaccines, we have compared the abilities of sequences encoding fragment C of tetanus toxin (FrC) and influenza A virus nucleoprotein (NP) to induce antibody or cytotoxic T-cell (CTL) responses in vivo. Strong antibody and CTL responses were induced against FrC targeted to the endoplasmic reticulum (ER) and both were reduced by removal of the leader sequence. In contrast, targeting of NP to the ER generated only a modest antibody response, likely due to misfolding in this site. Removal of the leader sequence led to anti-NP antibodies via cross-priming. For NP, induction of CTLs was not influenced by the leader sequence. Exogenous FrC or NP delivered as proteins were unable to induce CTLs. Routes to induction of optimal immune responses via DNA evidently differ according to the nature of the encoded pathogen sequence. Understanding processing pathways for pathogen sequences should assist rational design of DNA vaccines.
Asunto(s)
Presentación de Antígeno/genética , Nucleoproteínas/genética , Nucleoproteínas/inmunología , Fragmentos de Péptidos/genética , Fragmentos de Péptidos/inmunología , Proteínas de Unión al ARN , Toxina Tetánica/genética , Toxina Tetánica/inmunología , Vacunas de ADN/genética , Vacunas de ADN/inmunología , Proteínas del Núcleo Viral/genética , Proteínas del Núcleo Viral/inmunología , Animales , Anticuerpos Antibacterianos/biosíntesis , Anticuerpos Antibacterianos/sangre , Anticuerpos Antivirales/biosíntesis , Anticuerpos Antivirales/sangre , Células COS , Citotoxicidad Inmunológica/genética , Virus de la Influenza A/genética , Virus de la Influenza A/inmunología , Ratones , Ratones Endogámicos C57BL , Proteínas de la Nucleocápside , Señales de Clasificación de Proteína/genética , Linfocitos T Citotóxicos/inmunología , Linfocitos T Citotóxicos/microbiología , Linfocitos T Citotóxicos/virología , Transfección , Vacunas Sintéticas/genética , Vacunas Sintéticas/inmunología , Vacunas Virales/genética , Vacunas Virales/inmunologíaRESUMEN
A heterohybridoma cell line producing the human monoclonal antibody (MoAb) MDT.1 has been established. The heavy chain of MoAb MDT.1 is encoded by the VH gene segment V4-34 (previously designated VH4-21), and the light chain is encoded by the V kappa 1-L12a gene segment, both in germline configuration. MDT.1 has reactivity against lipid A, double- and single-stranded DNA, red blood cell associated i antigen, and ganglioside antigens. In a panel of tumour cell lines, MDT.1 reacted specifically with melanoma cells and other tumour cells of neuroectodermal origin. Cellular recognition appears to be via tumour-associated ganglioside antigens, and may involve the minimal essential epitope NeuNac alpha 2-->3Gal beta 1-->-4Glc-. Binding to ganglioside antigen is inhibited by the monoclonal anti-idiotypic antibody 9G4. Since the 9G4 idiotope is located in framework region 1 (FWR1) of V4-34-encoded antibodies, this region is likely to be involved, either directly or indirectly, in ganglioside binding. The complementarity-determining region 3 (CDR3) of MDT.1 is arginine rich, with five out of 12 residues being arginine and these residues are candidates for interaction with the negatively charged ganglioside. The ability of MoAb MDT.1 to recognise ganglioside antigens is associated with potentially useful anti-tumour activity.
Asunto(s)
Anticuerpos Monoclonales/genética , Gangliósidos/inmunología , Región Variable de Inmunoglobulina/inmunología , Melanoma/inmunología , Secuencia de Aminoácidos , Animales , Anticuerpos Monoclonales/inmunología , Autoantígenos/inmunología , Línea Celular , Epítopos , Humanos , Lípido A/inmunología , Ratones , Datos de Secuencia MolecularRESUMEN
DNA vaccines against cancer have to activate an inadequate or damaged immune system in order to attack residual cancer cells. Although the potential problem of tolerance may be overcome by transplantation, provision of high levels of T-cell help is likely to be an important factor in stimulating effective immune pathways. The fusion gene approach appears to provide the required help, and offers a rational design for raising both antibody and T-cell mediated attack against lymphoma and myeloma, which express idiotypic antigen at the cell surface or as a secreted protein respectively. Intriguingly, preliminary data indicate that the fusion gene approach promotes antibody responses against a different cell surface tumour antigen, CEA. Strategies for using DNA vaccines to induce attack on processed peptides bound to MHC class I molecules are also being developed. We hope and anticipate that all categories of tumour antigen may be susceptible to this powerful new technology. The critical clinical requirement, however, will be to treat the presenting tumour with maintenance or restoration of immune capacity. We await results of the preliminary clinical trials with great interest.
Asunto(s)
Vacunas contra el Cáncer/uso terapéutico , Neoplasias Hematológicas/terapia , Inmunoterapia Activa , Vacunas de ADN/uso terapéutico , Animales , ADN Complementario/genética , Neoplasias Hematológicas/inmunología , Humanos , Fragmentos de Inmunoglobulinas/genética , Fragmentos de Inmunoglobulinas/inmunología , Idiotipos de Inmunoglobulinas/genética , Idiotipos de Inmunoglobulinas/inmunología , Leucemia de Células B/inmunología , Leucemia de Células B/terapia , Linfoma de Células B/inmunología , Linfoma de Células B/terapia , Ratones , Regiones Promotoras GenéticasRESUMEN
OBJECTIVE: To compare the levels of the 9G4 idiotope (9G4 Id) in systemic lupus erythematosus (SLE) patients with a detailed disease activity index, the British Isles Lupus Assessment Group (BILAG) index, and serological parameters of disease activity by ds DNA antibody levels and serum C3 concentrations. METHODS: In a cross sectional analysis serum samples from 190 patients with SLE were studied and a further 55 serial bleeds from 14 patients. An enzyme linked immunosorbent assay was used to measure the 9G4 Id, and anti dsDNA and antimyeloperoxidase (MPO) antibodies. The C3 levels were measured by laser nephelometer. RESULTS: Seventy six of 190 (40%) of the patients tested had raised 9G4 Id levels. In the cross sectional study 9G4 Id levels were found to correlate with disease activity in the BILAG cardiovascular/respiratory renal, and haematological systems and with global BILAG score (p < 0.01). In the serial bleeds 9G4 Id levels correlated with anti-dsDNA antibody and C3 levels, but not with anti-MPO antibodies. No correlations were found with treatment. In six cases the 9G4 Id levels correlated well with global BILAG scores and dsDNA antibody levels. In four cases the BILAG global and 9G4 Id levels alone correlated well. CONCLUSIONS: Raised levels of the 9G4 Id are present in a substantial proportion of serum samples from patients with lupus, correlate with various aspects of disease activity in SLE. The Id is detectable on anti-dsDNA antibodies, though it must also be present on other immunoglobulins whose specificities remain unknown.
Asunto(s)
Idiotipos de Inmunoglobulinas/sangre , Lupus Eritematoso Sistémico/inmunología , Anticuerpos Antinucleares/sangre , Autoanticuerpos/sangre , Estudios Transversales , ADN/inmunología , Estudios de Seguimiento , Humanos , Lupus Eritematoso Sistémico/patología , Peroxidasa/inmunología , Índice de Severidad de la EnfermedadRESUMEN
Vaccination with idiotypic protein protects against B-cell lymphoma, mainly through anti-idiotypic antibody. For use in patients, DNA vaccines containing single-chain Fv derived from tumor provide a convenient alternative vaccine delivery system. However, single-chain Fv sequence alone induces low anti-idiotypic response and poor protection against lymphoma. Fusion of the gene encoding fragment C of tetanus toxin to single-chain Fv substantially promotes the anti-idiotypic response and induces strong protection against B-cell lymphoma. The same fusion design also induces protective immunity against a surface Ig-negative myeloma. These findings indicate that fusion to a pathogen sequence allows a tumor antigen to engage diverse immune mechanisms that suppress growth. This fusion design has the added advantage of overcoming potential tolerance to tumor that may exist in patients.
Asunto(s)
Vacunas contra el Cáncer , Fragmentos de Inmunoglobulinas , Región Variable de Inmunoglobulina , Linfoma de Células B/inmunología , Mieloma Múltiple/inmunología , Fragmentos de Péptidos/inmunología , Neoplasias del Bazo/terapia , Toxina Tetánica/inmunología , Vacunas de ADN , Animales , Inmunoglobulina M , Cadenas kappa de Inmunoglobulina , Linfoma de Células B/terapia , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos CBA , Mieloma Múltiple/terapia , Proteínas Recombinantes de Fusión/inmunologíaRESUMEN
SLE is an autoimmune disease characterized by the presence of autoantibodies against double-stranded (ds)DNA. A large proportion (approx. 40%) of patients with lupus also have increased levels of serum immunoglobulin encoded by the V(4-34) heavy chain gene, which often fluctuate with disease activity, and this gene is utilized by a subset of anti-dsDNA antibodies. In order to probe the nature of the V(4-34)-encoded immunoglobulin, B cells were isolated from the blood of two patients with active disease, using the 9G4 MoAb specific for the immunoglobulin gene product. Following cell picking, single-cell polymerase chain reaction (PCR) amplification of cDNA was used to investigate both V(H) and V(L) genes. Sequences were obtained from B cells synthesizing IgM (n = 10), IgG (n = 4) and IgA (n = 1). For V(H), all were derived from V(4-34) as expected, and the isotype-switched sequences and 2/6 IgM sequences were somatically mutated. In contrast, V(L) (12 kappa and 3 lambda) showed a low level of mutation, possibly indicating secondary rearrangements. The three most highly mutated V(H) sequences were associated with unmutated V(L) sequences. Analysis of the distribution of mutations revealed only minor clustering in complementarity-determining regions (CDRs) characteristic of antigen selection. The CDR3 lengths of V(H) ranged from five to 19 amino acids, and in 3/15 there was evidence of an excess of positively charged amino acids, compared with the normal expressed repertoire. Basic amino acids were also found at the V(L)-J(L) junctions in 4/15. These findings provide insight into the V(4-34)-V(L) gene combinations used by B cells in patients with SLE which might have clinical relevance.
Asunto(s)
Autoanticuerpos/genética , Linfocitos B/inmunología , Región Variable de Inmunoglobulina/genética , Lupus Eritematoso Sistémico/genética , Lupus Eritematoso Sistémico/inmunología , Adolescente , Adulto , Secuencia de Aminoácidos , Femenino , Genes de Inmunoglobulinas , Humanos , Cadenas Pesadas de Inmunoglobulina/genética , Idiotipos de Inmunoglobulinas/sangre , Cadenas Ligeras de Inmunoglobulina/genética , Persona de Mediana Edad , Datos de Secuencia MolecularRESUMEN
BACKGROUND/AIMS: Autoantibodies with specificity for the E2 component of the pyruvate dehydrogenase complex (PDC-E2) are commonly present in primary biliary cirrhosis. The aim of this study was to generate and characterise human anti-PDC-E2 monoclonal antibodies and analyse immunoglobulin gene usage and mutation for clues to pathogenesis. METHODS: Peripheral B-lymphocytes from two patients with primary biliary cirrhosis were used to generate heterohybridomas secreting PDC-E2 specific monoclonal antibodies. The antibodies were characterised by ELISA, immunoblotting, indirect immunofluorescence and enzyme inhibition techniques, and their encoding immunoglobulin genes were amplified, cloned and sequenced. RESULTS: Four IgGlambda and one IgMlambda monoclonal antibodies specific for PDC-E2 were generated: all gave bands at 74 kD and 52 kD on PDC immunoblots, two clones were specific for the lipoylated inner lipoyl domain, and all inhibited target enzyme function. Sequence analysis suggested unrestricted VH gene usage, but a strong preference for lambda light chains. The extent of somatic mutation was high (3-20%), with evidence for antigen selection in 3/5 VH sequences. CONCLUSIONS: These monoclonal antibodies closely resemble the hallmark autoantibodies of primary biliary cirrhosis. Their specificities demonstrate true cross reactivity between an epitope on PDC-E2 and Protein X, and the existence of a subset of B cells that recognise only the lipoylated form of the antigen. The pattern of immunoglobulin gene mutations suggests an antigen-driven selection of high affinity IgG autoantibodies, supporting a possible role for exogenous antigen in the pathogenesis of primary biliary cirrhosis.
Asunto(s)
Inmunogenética , Inmunoglobulina G/análisis , Inmunoglobulina M/análisis , Cirrosis Hepática Biliar/inmunología , Complejo Piruvato Deshidrogenasa/inmunología , Secuencia de Aminoácidos , Anticuerpos Monoclonales , Especificidad de Anticuerpos , Reacciones Antígeno-Anticuerpo , Acetiltransferasa de Residuos Dihidrolipoil-Lisina , Femenino , Código Genético , Humanos , Immunoblotting , Inmunoglobulina G/genética , Inmunoglobulina M/genética , Cirrosis Hepática Biliar/genética , Datos de Secuencia Molecular , MutaciónRESUMEN
We have characterized the reactivities of a panel of V4-34-encoded human IgM monoclonal antibodies (mAb) which bind the erythrocyte Rh D antigen, derived from an immunized individual. These were compared with the specificities of V4-34-encoded autoantibodies with I/i reactivity produced from patients with cold agglutinin disease (CAD), and other V4-34-encoded autoantibodies. The antibodies were evaluated for cold agglutinin activity using haemagglutination tests, immunofluorescence microscopy for reactivity with tissue components, and in solid phase radiobinding assays with purified antigens. We found that (i) cold agglutinin activity was a property of all the V4-34-encoded mAb (ii) the cold agglutinins from CAD patients were generally monospecific for I/i whereas most of the anti-D and the other V4-34-encoded mAb displayed multireactive properties, frequently binding to strongly acidic antigens (iii) computation of the net charge of the heavy-chain V regions showed that the multireactive mAb were generally more positively charged than the monospecific cold agglutinins, which could contribute to their multireactive phenotype. The involvement of charge interactions was further indicated by the effects of pH and ionic strength on the immunofluorescence staining patterns.
Asunto(s)
Aglutininas/inmunología , Anticuerpos Monoclonales/genética , Autoanticuerpos/inmunología , Cadenas Pesadas de Inmunoglobulina/inmunología , Región Variable de Inmunoglobulina/inmunología , Adulto , Secuencia de Aminoácidos , Anemia Hemolítica Autoinmune/inmunología , Anticuerpos Monoclonales/química , Anticuerpos Monoclonales/inmunología , Crioglobulinas , Pruebas de Hemaglutinación , Humanos , Concentración de Iones de Hidrógeno , Inmunoglobulina M/inmunología , Filamentos Intermedios/inmunología , Isoanticuerpos/inmunología , Sistema del Grupo Sanguíneo Rh-Hr/inmunología , Globulina Inmune rho(D)RESUMEN
Idiotypic determinants can act as tumor-associated Ags for B cell lymphoma. Vaccination with idiotypic protein and adjuvant is known to induce specific protection against lymphoma challenge in mice, largely mediated by anti-idiotypic Ab. For facilitating the approach for patients, the V(H) and V(L) genes used to encode the individual idiotypic determinants of each tumor can be obtained by PCR and assembled as single chain Fv (scFv). DNA vaccines containing scFv sequences alone induce low and poorly reproducible levels of anti-idiotypic Ab, likely to be insufficient to suppress tumor in patients. In addition, it may be necessary to break tolerance to Id in tumor bearers. By fusing the gene for fragment C of tetanus toxin to the C terminus of human scFv, we have promoted the anti-scFv Ab response in mice by >50-fold in three of three cases. The induced Abs are mainly against idiotypic determinants, and react specifically with patients' tumor cells, indicating optimal folding of the scFv molecule in the fusion protein. For both antigenic components of the DNA vaccine, the IgG subclass distribution showed a relative increase in IgG2a as compared with vaccination with IgM protein in adjuvant. In patients, the fusion gene should both promote anti-idiotypic Ab and induce Abs against fragment C of tetanus toxin. The latter response would provide a potentially useful comparative measure of the ability of patients to respond to conventional Ag delivered via DNA.
Asunto(s)
Anticuerpos Antiidiotipos/biosíntesis , Vacunas contra el Cáncer/inmunología , Fragmentos de Inmunoglobulinas/genética , Linfoma/prevención & control , Proteínas Recombinantes de Fusión/inmunología , Toxina Tetánica/genética , Vacunas de ADN/inmunología , Secuencia de Aminoácidos , Animales , Humanos , Sueros Inmunes/inmunología , Fragmentos de Inmunoglobulinas/inmunología , Ratones , Ratones Endogámicos BALB C , Datos de Secuencia Molecular , Toxina Tetánica/inmunologíaAsunto(s)
Vacunas contra el Cáncer , ADN , Linfoma/terapia , Neoplasias/terapia , Anticuerpos Antiidiotipos/biosíntesis , Anticuerpos Antiidiotipos/genética , Formación de Anticuerpos , Vectores Genéticos , Humanos , Fragmentos de Inmunoglobulinas/biosíntesis , Fragmentos de Inmunoglobulinas/genética , Región Variable de Inmunoglobulina/biosíntesis , Región Variable de Inmunoglobulina/genética , Linfoma/inmunología , Neoplasias/inmunologíaAsunto(s)
Anticuerpos Antinucleares/genética , Bacteriófago M13/genética , ADN/inmunología , Genes de Inmunoglobulinas/genética , Inmunoglobulina G/genética , Idiotipos de Inmunoglobulinas/genética , Región Variable de Inmunoglobulina/genética , Anticuerpos Antinucleares/inmunología , Eritrocitos/inmunología , Genes de Inmunoglobulinas/inmunología , Humanos , Fragmentos Fab de Inmunoglobulinas/genética , Fragmentos Fab de Inmunoglobulinas/inmunología , Inmunoglobulina G/inmunología , Cadenas Pesadas de Inmunoglobulina/genética , Cadenas Pesadas de Inmunoglobulina/inmunología , Idiotipos de Inmunoglobulinas/inmunología , Cadenas Ligeras de Inmunoglobulina/genética , Cadenas Ligeras de Inmunoglobulina/inmunología , Región Variable de Inmunoglobulina/inmunologíaRESUMEN
We have previously described complement-independent killing of human B lymphocytes by two IgM MoAbs derived from the VH4-34 (VH4.21) gene. Analysis of 17 independently derived VH4-34-encoded MoAbs shows that B cell toxicity is not limited to the two described MoAbs, but is a general property shared by a subset of MoAbs derived from the VH4-34 gene. As observed by two independent microscopy techniques, giant membrane pores were formed on target B cells within 10-15 min of exposure to cytotoxic VH4-34-derived MoAbs. Toxicity by individual MoAb correlated directly to its B cell binding intensity measured by FACS, i.e. stronger the binding greater the killing. Sequence analysis showed that V(H) region in germ-line or in near germ-line configuration was necessary but not sufficient for B cell binding. In addition, a particular sequence motif enriched in basic amino acids in the CDR3 may be required to supplement the reactivity mediated by the V(H) region of the MoAb molecule. VH4-34-encoded antibodies that fulfil the above sequence requirements have cold agglutinin activity towards the i antigen of cord erythrocytes. In vivo, such anti-i/anti-B cell antibodies are rarely detected in healthy adults, but serum levels are dramatically elevated in selective pathological conditions, such as systemic lupus erythematosus and infectious mononucleosis. This strict regulation may be related to the novel and rapid mechanism of human B cell toxicity demonstrated by antibodies encoded by a single human V(H) gene.